Your browser doesn't support javascript.
loading
Koch Institute Symposium on Cancer Immunology and Immunotherapy.
Drake, Adam; Joshi, Nikhil S; Szeto, Gregory L; Zhu, Eric; Eisen, Herman N; Irvine, Darrell J.
Afiliação
  • Drake A; Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139.
  • Joshi NS; Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139.
  • Szeto GL; Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139.
  • Zhu E; Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139 ; Dept. of Chemical Engineering, Massachusetts Institute of Technology, Cambridge, MA 02139.
  • Eisen HN; Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139 ; Dept. of Biology, Massachusetts Institute of Technology, Cambridge, MA 02139.
  • Irvine DJ; Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139 ; Dept. of Biological Engineering, Massachusetts Institute of Technology, Cambridge, MA 02139 ; Dept. of Materials Science & Engineering, Massachusetts Institute of Technology, Cambridge, M
Cancer Immunol Res ; 1: 217-222, 2013 Oct.
Article em En | MEDLINE | ID: mdl-24466562
ABSTRACT
The 12th annual summer symposium of The Koch Institute for Integrative Cancer Research at MIT was held in Cambridge, MA, on June 14th, 1023. The symposium entitled "Cancer Immunology and Immunotherapy" focused on recent advances in preclinical research in basic immunology and biomedical engineering, and their clinical application in cancer therapies. The day-long gathering also provided a forum for discussion and potential collaborations between engineers and clinical investigators. The major topics presented include (i) enhancement of adoptive cell therapy by engineering to improve the ability and functionality of T-cells against tumor cells; (ii) current therapies using protein and antibody therapeutics to modulate endogenous anti-tumor immunity; and (iii) new technologies to identify molecular targets and assess therapeutic efficacy, and devices to control and target drug delivery more effectively and efficiently.

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2013 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2013 Tipo de documento: Article